- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Interventions
- VS-01 on top of SOC (Active Treatment Group), SOC
- Drug
- Lead sponsor
- Genfit
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatic Encephalopathy, Cirrhosis
- Interventions
- Rifaximin, Lactulose
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 43
- States / cities
- Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
- Conditions
- Hepatic Encephalopathy, Cirrhosis
- Interventions
- Resistant Potato Starch
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota
- Conditions
- Hepatic Encephalopathy
- Interventions
- Placebo, Rifaximin
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 22 more
- Conditions
- Overt Hepatic Encephalopathy
- Interventions
- 40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 34
- States / cities
- Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
- Interventions
- ornithine phenylacetate, placebo intravenous infusion
- Drug
- Lead sponsor
- Ocera Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
- Conditions
- Hepatic Encephalopathy
- Interventions
- AXA1665, Placebo
- Drug
- Lead sponsor
- Axcella Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 21
- States / cities
- San Francisco, California • DeBary, Florida • Gainesville, Florida + 15 more